Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1

Amino Acid Regulation of TOR Complex 1.

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

Regulation of mTORC1 by the Rag GTPases

A multiprotein signaling complex sustains AKT and mTOR/S6K activity necessary for the survival of cancer cells undergoing stress

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

Tsc Tumour Suppressor Proteins Antagonize Amino-Acid–tor Signalling

Regulation of mTORC1 by Upstream Stimuli

Regulation Of Mtorc1 By The Rab And Arf Gtpases

ArfGAP1 inhibits mTORC1 lysosomal localization and activation

The Rag GTPase Regulates the Dynamic Behavior of TSC Downstream of Both Amino Acid and Growth Factor Restriction

CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth

Architecture of the human GATOR1 and GATOR1–Rag GTPases complexes

GPCR Signaling Inhibits Mtorc1 Via PKA Phosphorylation of Raptor

Rag-Ragulator is the central organizer of the physical architecture of the mTORC1 nutrient-sensing pathway

AKAP13 Couples GPCR Signaling to Mtorc1 Inhibition

Nutrient regulation of mTORC1 at a glance

Redundant electrostatic interactions between GATOR1 and the Rag GTPase heterodimer drive efficient amino acid sensing in human cells

mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.